A Single Center, Multiple-dose, Non-randomized, Dose Adjustment, Open-Label Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Tolerability of Oshadi Icp in Patients With Type 1 Diabetes Mellitus -A Phase II Clinical Study

Trial Profile

A Single Center, Multiple-dose, Non-randomized, Dose Adjustment, Open-Label Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Tolerability of Oshadi Icp in Patients With Type 1 Diabetes Mellitus -A Phase II Clinical Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2016

At a glance

  • Drugs Insulin (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Oshadi Drug Administration
  • Most Recent Events

    • 28 Mar 2016 Planned End Date changed from 1 Oct 2016 to 1 Jun 2017 as per ClinicalTrials.gov record.
    • 28 Mar 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Feb 2017 as per ClinicalTrials.gov record.
    • 21 Apr 2015 Planned End Date changed from 1 Mar 2015 to 1 Oct 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top